Company Profile
Aldeyra Therapeutics, Inc. Stock Price, News & Analysis
Company overview
Business overview
Aldeyra Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Aldeyra Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Aldeyra Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Aldeyra Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
ALDX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Aldeyra’s catalysts are reproxalap and the dry-eye / ophthalmology regulatory path, where the next step can materially move the stock. The company is still very event-driven.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.